H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $44 from $42 and keeps a Buy rating on the shares following the Q4 report. The firm believes OCS-01 has the potential to be the first topical eye drop approved to treat of diabetic macular edema. Oculis is on track to report topline data in Q2, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis: Strengthened Balance Sheet and Advancing Late-Stage Pipeline Support Buy Rating and Higher $40 Target Ahead of 2026 Pivotal Readouts
- Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline
- Oculis reports Q4 EPS (CHF 0.42c) vs. (CHF 0.67) last year
- Oculis Holding Ag (OCS) Q4 Earnings Cheat Sheet
- J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ Stocks